Reported Earlier, NeuroBo's Novel Drug Shows Results for Weight Loss at ADA 2024
Reported Earlier, NeuroBo's Novel Drug Shows Results for Weight Loss at ADA 2024
早先報道，神經博士的新型藥物在2024年ADA（美國糖尿病協會）展示了減重的效果。
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models. Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center, will present the data today, in a poster at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21-24, in Orlando, Florida.